ASMB claims that an acceptable endpoint for FDA approval of a new HBV drug is absence of HBV DNA six months* after terminating treatment, without regard to HBsAg levels.
*ASMB acknowledges that the duration of the off-treatment period is not set in stone and could be longer than six months.
Market Data 
Markets 
AI
